Autor: |
Mattheos Savvides, Stergios Polyzos, Christos Georgopoulos, Sideris Delaroudis |
Předmět: |
|
Zdroj: |
Journal of Bone & Mineral Metabolism; Jan2010, Vol. 28 Issue 1, p108-110, 3p |
Abstrakt: |
Abstract  Intermittent exogenous parathyroid hormone (PTH) is a potent osteoanabolic agent used for the treatment of severe osteoporosis. Two molecules of recombinant PTH are commercially available: the full-length PTH (PTH 1â84) and teriparatide (PTH 1â34). We present the first report of PTH-induced mild, asymptomatic, normochromic normocytic anemia in a postmenopausal woman treated sequentially with PTH 1â84 and PTH 1â34. Anemia was more pronounced with PTH 1â84 compared to PTH 1â34 and was reversed with each regimen discontinuation. We suggest monitoring of hematocrit and hemoglobin in PTH-treated patients, especially when PTH 1â84 is used. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|